Literature DB >> 24253338

The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging.

Gwendolin Manegold-Brauer1, Anjeung Kang Bellin, Sevgi Tercanli, Olav Lapaire, Viola Heinzelmann-Schwarz.   

Abstract

Ovarian cancer is the most aggressive gynecologic malignancy, with a 5-year survival rate ranging around 40%. A crucial factor influencing the prognosis is early detection of a suspicious mass and referral to a gynecologic oncology center for further diagnosis, staging and debulking surgery. Here, we present the different imaging methods ultrasound (US), magnetic resonance imaging, computer tomography (CT) and 18F-fluoro-deoxyglucose positron emission tomography (PET)/CT that are used for the characterization, diagnosis, staging and surveillance of ovarian cancer. In this review, we focus on US and discuss in detail the advantages and the limitations, as well as the appropriate indications for each of the individual imaging techniques.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24253338     DOI: 10.1007/s00404-013-3081-8

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  9 in total

1.  Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors.

Authors:  Rafał Watrowski; Georg Heinze; Christoph Jäger; Johannes Forster; Robert Zeillinger
Journal:  Tumour Biol       Date:  2016-05-20

Review 2.  In 2014, can we do better than CA125 in the early detection of ovarian cancer?

Authors:  Joshua G Cohen; Matthew White; Ana Cruz; Robin Farias-Eisner
Journal:  World J Biol Chem       Date:  2014-08-26

3.  Simple laboratory score improves the preoperative diagnosis of adnexal mass.

Authors:  Rafał Watrowski; Robert Zeillinger
Journal:  Tumour Biol       Date:  2015-10-23

4.  Murine model for non-invasive imaging to detect and monitor ovarian cancer recurrence.

Authors:  Natalia J Sumi; Eydis Lima; John Pizzonia; Sean P Orton; Vinicius Craveiro; Wonduk Joo; Jennie C Holmberg; Marta Gurrea; Yang Yang-Hartwich; Ayesha Alvero; Gil Mor
Journal:  J Vis Exp       Date:  2014-11-02       Impact factor: 1.355

5.  Borderline ovarian tumors and diagnostic dilemma of intraoperative diagnosis: could preoperative He4 assay and ROMA score assessment increase the frozen section accuracy? A multicenter case-control study.

Authors:  Salvatore Gizzo; Roberto Berretta; Stefania Di Gangi; Maria Guido; Giuliano Carlo Zanni; Ilaria Franceschetti; Michela Quaranta; Mario Plebani; Giovanni Battista Nardelli; Tito Silvio Patrelli
Journal:  Biomed Res Int       Date:  2014-11-05       Impact factor: 3.411

6.  Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.

Authors:  Maria C Katapodi; Valeria Viassolo; Maria Caiata-Zufferey; Christos Nikolaidis; Nicole Buerki; Karl Heinimann; Viola Heinzelmann-Schwarz; Olivia Pagani; Pierre O Chappuis; Rosmarie Bührer-Landolt; Rossella Graffeo; Henrik Csaba Horváth; Christian Kurzeder; Manuela Rabaglio; Michael Scharfe; Corinne Urech; Tobias E Erlanger; Nicole Probst-Hensch
Journal:  JMIR Res Protoc       Date:  2017-09-20

7.  Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses.

Authors:  Wan Kyu Eo; Ki Hyung Kim; Eun Joo Park; Heung Yeol Kim; Hong-Bae Kim; Suk Bong Koh; Jeong Namkung
Journal:  J Cancer       Date:  2018-03-08       Impact factor: 4.207

8.  Utility of Preoperative Inflammatory Markers to Distinguish Epithelial Ovarian Cancer from Benign Ovarian Masses.

Authors:  Lian Li; Jing Tian; Liwen Zhang; Luyang Liu; Chao Sheng; Yubei Huang; Hong Zheng; Fengju Song; Kexin Chen
Journal:  J Cancer       Date:  2021-03-05       Impact factor: 4.207

9.  A Novel Classifier Based on Urinary Proteomics for Distinguishing Between Benign and Malignant Ovarian Tumors.

Authors:  Maowei Ni; Jie Zhou; Zhihui Zhu; Jingtao Yuan; Wangang Gong; Jianqing Zhu; Zhiguo Zheng; Huajun Zhao
Journal:  Front Cell Dev Biol       Date:  2021-08-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.